PFS curves according to parameters used in the model. PFS of (A) MRD⁻ and MRD⁺ patients after ASCT (IFM 2009), (B) Second-line DKd, Kd (CANDOR), and KRd (ASPIRE), (C) EloPd (ELOQUENT-3), and (D) panobinostat-Bd (PANORAMA-1). Survival curves are shown from published clinical trials; curves marked “estimated” in the key were calculated using the model.